Controversies Section Editor: Phil B. Fontanarosa,
MD, Executive Deputy Editor.
Author Affiliation: Law Office of Joseph D.
Piorkowski, Jr, and Georgetown University Law Center, Washington, DC.
Published online November 22, 2004 (doi:10.1001/jama.292.21.2655).
JAMA has invited this response from Bayer Corporation
to the article authored by Psaty et al (the “Article”), which
appears on page 2622 in this issue. Although the Article is presented as a
scientific review of facts, sections are copied verbatim from a report submitted
by the lead author in a US lawsuit in which he served as a paid expert for
the plaintiff. Moreover, the Article’s conclusions are based upon selected
exhibits from another lawsuit in which another author (Dr Ray) submitted a
report for plaintiffs. Bayer won that court case (as well as the only other
cerivastatin cases that have gone to trial). At least 2 of the authors continue
to participate in lawsuits against Bayer.
Piorkowski JD. Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”. JAMA. 2004;292(21):2655-2657. doi:10.1001/jama.292.21.2655